Funded Projects › HORIZON
LifeLUNG · Improving Life expectancy of LUNG transplant recipients through innovative ex vivo perfusion gene therapy
Patient survival after lung transplantation (LTx) for end-stage pulmonary disease is poor (5-year survival rate of 59%) due to ischemia reperfusion injury (IRI) and graft rejection. No therapies are available to prevent IRI, and current immunosuppression causes toxicity and morbidity. Novel strategies are required that can mask the graft from the recipient’s immune systemThe LifeLUNG initiative unites the critical building blocks available in Europe to advance towards a novel paradigm for LTx. Ex vivo lung perfusion (EVLP) is a clinically used platform to maintain active lung physiology outside the body, making pre-LTx organ engineering a reality. The project aims to advancing EVLP technology to enhance our understanding of transplant rejection through accessible models. By utilizing biobanks of lung biopsies from both clinical LTx cases and established animal models of IRI and rejection, LifeLUNG will apply advanced machine learning and AI-driven deep sequencing to identify key immune factors and gene targets. The latter will be targeted in LifeLUNG with gene therapeutic agents (GTAs) that can be delivered during EVLP to selectively modulate immune responses. Several delivery tools including adeno-associated viral vectors, virus-like particles and lipid nanoparticles, will be tailored to ensure precise and graft-specific gene modulation, enhancing the therapeutic potential for reducing IRI and preventing rejection. Also the efficient production strategies of these GTAs will be an integral part of LifeLUNG. In parallel, LifeLUNG will explore the economic and ethical paradigms of genetic modification of lung transplantation and reflect its implementation into the broader research and clinical framework. The interdisciplinary nature of LifeLUNG will support the training of 15 doctoral candidates across clinical, academic, and industrial sectors, fostering collaboration and the development of transferable skills to advance the research objectives.
Consortium · 24 organisations
KATHOLIEKE UNIVERSITEIT LEUVEN
BE · €1,057,980
MEDIZINISCHE UNIVERSITAET WIEN
AT · €302,543
MILTENYI BIOTEC BV & CO KG
DE · €290,272
AARHUS UNIVERSITET
DK · €335,890
Mary Ann Liebert, Inc.
US
LUNDS UNIVERSITET
SE · €324,630
UNIVERSITAT INTERNACIONAL DE CATALUNYA
ES
UNIVERSITAT BASEL
CH
HALO, Patiëntenvereniging longtransplantatie UZ Leuven
BE
OMNISCOPE ESPANA SL
ES · €282,188
ASTRAZENECA AB
SE
STICHTING EUROTRANSPLANT INTERNATIONAL FOUNDATION
NL
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
NL · €305,286
ANTLERON
BE · €96,180
UNIVERSITAT DE BARCELONA
ES
QbD Group Austria GmbH
AT
ASSOCIATION HOPITAL FOCH
FR · €314,669
FUNDACION HITT
ES · €282,188
UNIVERSITE PARIS-SACLAY
FR
UNIVERSITEIT UTRECHT
NL
EBERHARD KARLS UNIVERSITAET TUEBINGEN
DE · €290,272
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
FR
UNIVERSITY COLLEGE LONDON
UK · €348,738
XVIVO PERFUSION AKTIEBOLAG
SE
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.